Tempus xE Whole Exome
Use
The Tempus xE is a comprehensive whole exome sequencing panel that covers over 19,000 genes. It provides potentially actionable and biologically relevant alterations, including Tumor Mutational Burden (TMB). The test also includes potential germline findings in a limited set of 110 genes based on ACMG recommendations, NCCN Guidelines, and other literature, although it is not used as a validated germline panel. The clinical insights from the test might not just be related to the patient’s current cancer diagnosis but can include hereditary cancer and non-cancer related genes.
Special Instructions
xE can be ordered as a standalone test or in combination with xR. Ordering can be streamlined via the Tempus Hub, EHR systems, or paper requisitions. The test requires specimens with a tumor content of at least 40% post macrodissection. Normal match sequencing is performed to ensure somatic variant calling fidelity.
Limitations
Tempus xE is not a validated germline panel, and germline findings should not be used for hereditary cancer risk determination. Detection limits and sensitivity/specificity metrics vary by variant type (e.g., SNVs and indels have a 10% VAF detection limit with high sensitivity and specificity, while copy number gains require 30% tumor purity with specific performance metrics). The test provides data-driven precision medicine insights but is not suitable as the sole basis for diagnosing hereditary diseases without further confirmatory testing.
Methodology
NGS (WES)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Requires specimens with tumor content of at least 40% post macrodissection.